Key statistics
On Friday, Arcus Biosciences Inc (RCUS:NYQ) closed at 18.92, -28.33% below its 52-week high of 26.40, set on Dec 09, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 20.17 |
|---|---|
| High | 20.53 |
| Low | 18.81 |
| Bid | 17.63 |
| Offer | 22.50 |
| Previous close | 19.96 |
| Average volume | 920.63k |
|---|---|
| Shares outstanding | 122.86m |
| Free float | 85.89m |
| P/E (TTM) | -- |
| Market cap | 2.32bn USD |
| EPS (TTM) | -3.43 USD |
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
More ▼
- Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2025 Financial Results and Pipeline Updates
- Arcus Biosciences Announces New Employment Inducement Grants
- Arcus Outlines 2026 Plans for Casdatifan, its Potential Best-in-Class HIF-2a Inhibitor, and its Inflammation Programs
- Arcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare Conference
- Arcus Provides Update on Phase 3 STAR-221 Study and Concentrates Its R&D Investment on Casdatifan and Emerging Inflammation and Immunology Portfolio
- Arcus Biosciences Announces New Employment Inducement Grants
- Arcus Biosciences to Participate in Two Upcoming Investor Conferences
More ▼
